BioCentury | May 1, 2020

Skyrizi continues to outperform as AbbVie looks to fill Humira gap

Despite the effects of the COVID-19 outbreak, AbbVie now expects 2020 sales of psoriasis drug Skyrizi to reach about $1.4 billion as the therapy again exceeded expectations in the year’s first quarter, suggesting the company...
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

Lilly announced positive Phase III data for autoimmune disease candidate mirikizumab and attributed a bump in revenue, adjusted guidance and trial delays to the COVID-19 pandemic. As part of its 1Q20 earnings, Eli Lilly and...
BioCentury | Mar 23, 2020
Product Development

Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

Lilly’s decision to delay most clinical trial starts and suspend enrollment in most ongoing trials makes it the latest and largest biopharma to acknowledge a broad impact of the COVID-19 outbreak on its development plans...
BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

Dermatitis, pneumonia vaccine data for Pfizer  Pfizer Inc. (NYSE:PFE) reported Phase III data for atopic dermatitis therapy abrocitinib and pneumococcal vaccine 20vPnC Wednesday. The JAK-1 inhibitor met the co-primary efficacy endpoints vs. placebo in the...
BioCentury | Feb 8, 2020

Skyrizi’s the limit? AbbVie forecasts blockbuster year for psoriasis drug

In newly released guidance Friday, AbbVie projected $1.2 billion in 2020 sales of Skyrizi after the drug far surpassed sales expectations in its first several months on the market. Sales of Skyrizi risankizumab-rzaa climbed to...
BC Extra | Jan 27, 2020
Company News

AZ regains brazikumab rights as AbbVie paves way for closure of $63B takeout of Allergan

AstraZeneca is regaining a late-stage immunology program from Allergan in a deal designed to clear the way for U.S. and EU regulators to approve AbbVie’s $63 billion takeover of Allergan. AstraZeneca plc (LSE:AZN; NYSE:AZN) told...
BC Extra | Dec 27, 2019
Company News

With Zejula’s third local approval, Zai ready for mainland China launch

China’s approval of Zejula gives Zai Lab its first approval in mainland China and allows the company to start marketing the PARP inhibitor in the largest of the three markets in which it holds rights....
BC Extra | Nov 1, 2019
Company News

Skyrizi launch beats expectations again as AbbVie looks to post-Humira future

Recently launched psoriasis drug Skyrizi exceeded sales expectations for the second quarter in a row, as immunology and hemato-oncology drugs continue to drive AbbVie’s growth ahead of anticipated U.S. biosimilar competition for Humira. Sales of...
BC Extra | Aug 13, 2019
Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

Eli Lilly said Taltz was superior to J&J's Tremfya in treating psoriasis at 12 weeks in the Phase IV IXORA-R trial, but the data may not move the needle on physicians’ prescribing habits. The data...
BC Innovations | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...
Items per page:
1 - 10 of 343